OBJECTIVE: To determine the role of p38 mitogen-activated protein kinase (MAPK) signaling in endotoxin-induced liver injury. BACKGROUND: MAPKs have been reported to play a potential role in regulating inflammatory responses, but the role of p38 MAPK signaling in chemokine production, leukocyte recruitment, and hepatocellular apoptosis in the liver of endotoxemic mice is not known. METHODS: Endotoxin-induced leukocyte-endothelium interactions were studied by use of intravital fluorescence microscopy in the mouse liver. Tumor necrosis factor-alpha (TNF-alpha) and CXC chemokines, liver enzymes, and apoptosis were determined 6 hours after endotoxin challenge. The specific p38 MAPK inhibitor SB 239063 was given immediately prior to endotoxin exposure. Phosphorylation and activity of p38 MAPK were determined by immunoprecipitation and Western blot. RESULTS: Endotoxin increased phosphorylation and activity of p38 MAPK in the liver, which was markedly inhibited by SB 239063. Inhibition of p38 MAPK signaling dose-dependently decreased endotoxin-induced leukocyte rolling, adhesion, and sinusoidal sequestration of leukocytes. SB 239063 markedly reduced endotoxin-induced formation of TNF-alpha and CXC chemokines in the liver. Indeed, the endotoxin-provoked increase of liver enzymes and hepatocellular apoptosis were abolished and sinusoidal perfusion was restored in endotoxemic mice treated with SB 239063. CONCLUSIONS: This study demonstrates that p38 MAPK signaling plays an important role in regulating TNF-alpha and CXC chemokine production in endotoxemic liver injury and that inhibition of p38 MAPK activity abolishes endotoxin-induced leukocyte infiltration as well as hepatocellular apoptosis. These novel findings suggest that interference with the p38 MAPK pathway may constitute a therapeutic strategy against septic liver damage.
OBJECTIVE: To determine the role of p38 mitogen-activated protein kinase (MAPK) signaling in endotoxin-induced liver injury. BACKGROUND: MAPKs have been reported to play a potential role in regulating inflammatory responses, but the role of p38 MAPK signaling in chemokine production, leukocyte recruitment, and hepatocellular apoptosis in the liver of endotoxemic mice is not known. METHODS: Endotoxin-induced leukocyte-endothelium interactions were studied by use of intravital fluorescence microscopy in the mouse liver. Tumor necrosis factor-alpha (TNF-alpha) and CXC chemokines, liver enzymes, and apoptosis were determined 6 hours after endotoxin challenge. The specific p38 MAPK inhibitor SB 239063 was given immediately prior to endotoxin exposure. Phosphorylation and activity of p38 MAPK were determined by immunoprecipitation and Western blot. RESULTS: Endotoxin increased phosphorylation and activity of p38 MAPK in the liver, which was markedly inhibited by SB 239063. Inhibition of p38 MAPK signaling dose-dependently decreased endotoxin-induced leukocyte rolling, adhesion, and sinusoidal sequestration of leukocytes. SB 239063 markedly reduced endotoxin-induced formation of TNF-alpha and CXC chemokines in the liver. Indeed, the endotoxin-provoked increase of liver enzymes and hepatocellular apoptosis were abolished and sinusoidal perfusion was restored in endotoxemic mice treated with SB 239063. CONCLUSIONS: This study demonstrates that p38 MAPK signaling plays an important role in regulating TNF-alpha and CXC chemokine production in endotoxemic liver injury and that inhibition of p38 MAPK activity abolishes endotoxin-induced leukocyte infiltration as well as hepatocellular apoptosis. These novel findings suggest that interference with the p38 MAPK pathway may constitute a therapeutic strategy against septic liver damage.
Authors: A Nagahira; K Nagahira; H Murafuji; K Abe; K Magota; M Matsui; S Oikawa Journal: Biochem Biophys Res Commun Date: 2001-03-09 Impact factor: 3.575
Authors: M D Josephs; F R Bahjat; K Fukuzuka; R Ksontini; C C Solorzano; C K Edwards; C L Tannahill; S L MacKay; E M Copeland; L L Moldawer Journal: Am J Physiol Regul Integr Comp Physiol Date: 2000-05 Impact factor: 3.619
Authors: F C Barone; E A Irving; A M Ray; J C Lee; S Kassis; S Kumar; A M Badger; R F White; M J McVey; J J Legos; J A Erhardt; A H Nelson; E H Ohlstein; A J Hunter; K Ward; B R Smith; J L Adams; A A Parsons Journal: J Pharmacol Exp Ther Date: 2001-02 Impact factor: 4.030
Authors: D C Underwood; R R Osborn; C J Kotzer; J L Adams; J C Lee; E F Webb; D C Carpenter; S Bochnowicz; H C Thomas; D W Hay; D E Griswold Journal: J Pharmacol Exp Ther Date: 2000-04 Impact factor: 4.030
Authors: T van der Poll; A Marchant; W A Buurman; L Berman; C V Keogh; D D Lazarus; L Nguyen; M Goldman; L L Moldawer; S F Lowry Journal: J Immunol Date: 1995-12-01 Impact factor: 5.422
Authors: Robert A Finkelstein; Yongqing Li; Baoling Liu; Fahad Shuja; Eugene Fukudome; George C Velmahos; Marc deMoya; Hasan B Alam Journal: J Surg Res Date: 2010-05-10 Impact factor: 2.192
Authors: Michael Hammer; Bernd Echtenachter; Heike Weighardt; Katrin Jozefowski; Stefan Rose-John; Daniela N Männel; Bernhard Holzmann; Roland Lang Journal: Immunology Date: 2010-11 Impact factor: 7.397
Authors: Fatemeh Fattahi; Miriam Kalbitz; Elizabeth A Malan; Elizabeth Abe; Lawrence Jajou; Markus S Huber-Lang; Markus Bosmann; Mark W Russell; Firas S Zetoune; Peter A Ward Journal: FASEB J Date: 2017-06-01 Impact factor: 5.191
Authors: Nabil Mohamed Selim; Abdullah Abdurrahman Elgazar; Nabil Mohie Abdel-Hamid; Mohammed Rizk Abu El-Magd; Aziz Yasri; Hala Mohamed El Hefnawy; Mansour Sobeh Journal: Antioxidants (Basel) Date: 2019-09-03